论文部分内容阅读
目的 研究PET对恶性淋巴瘤分期和治疗后评估的临床价值。方法 在初诊时或复发治疗前对 35例恶性淋巴瘤 ,包括霍奇金式淋巴瘤和非何杰金式淋巴瘤进行PET检查 ,部分病例尚进行全身CT扫描 ,WHO分类标准进行诊断。结果 PET对初诊淋巴瘤患者的敏感性为 93.5 % (2 9/ 31) ,PET与CT的一致性为 70 % (12 / 17) ;另有 5例患者的分期结果不一致 ,不一致性为 2 9%。追踪检查发现 ,PET检测复发或微小残留病的敏感率 88% (8/ 9) ,准确性 75 % (6 / 8)。在经过 6～ 8个周期的CHOP方案化疗后 ,5 0 % (4/ 8)的进展期NHL患者仍有残留病灶。结论 PET在恶性淋巴瘤的诊断 ,分期和治疗后评估比CT敏感 ,尤其是在微小残留病方面
Objective To study the clinical value of PET in staging and post-treatment evaluation of malignant lymphoma. Methods Totally 35 patients with malignant lymphoma, including Hodgkin’s lymphoma and non-Hodgkin’s lymphoma, were examined with PET before or at the time of first diagnosis and treatment. In some cases, whole body CT scan and WHO classification criteria were used for diagnosis. Results The sensitivity of PET was 93.5% (29/31) in patients with newly diagnosed lymphoma, and the consistency between PET and CT was 70% (12/17). The staging results of 5 patients were also inconsistent, with an inconsistency of 2 9 %. The follow-up examination found that the sensitivity rate of PET detection of recurrent or minimal residual disease was 88% (8/9) and the accuracy was 75% (6/8). After 6 to 8 cycles of CHOP regimen chemotherapy, 50% (4 of 8) of patients with advanced NHL have residual disease. Conclusions PET is more sensitive than CT in the diagnosis, staging and post-treatment of malignant lymphoma, especially in the area of minimal residual disease